Search

Your search keyword '"Kung, Andrew L."' showing total 1,393 results

Search Constraints

Start Over You searched for: Author "Kung, Andrew L." Remove constraint Author: "Kung, Andrew L."
1,393 results on '"Kung, Andrew L."'

Search Results

102. Supplementary Figure Legend from Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

104. Supplemental Figure 2 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

105. Supplementary Table 3 from Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion–Driven Cancer

106. Supplementary Methods, Figure Legends from Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer

107. Supplementary Fig. S1 from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

108. Supplementary Figure 4 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

109. Data from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

110. Supplementary Figure 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

111. Data from Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia

112. Supplementary Figure from Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia

113. Supplementary Figure Legends from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

114. Supplementary Tables S1-S3 and Supplementary Figures S1-S6 from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

115. Supplementary Table 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

116. Supplementary Figure 1 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

118. Supplementary Figure 6 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

119. Supplementary Figure 4 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

120. Supplementary Figure Legends from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

121. Supplementary Figure 5F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

122. Supplementary Methods from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

123. Supplementary Figure 5A-5E from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

124. Supplementary Figure 8 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

126. Supplementary Figure 2 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

127. Supplementary Figures from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer

128. Supplementary Figure 3C-3F from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

129. Supplementary Table S1 from Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

130. Supplementary Methods from Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer

131. Supplementary Figure 2 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

132. Supplementary Figures 1 - 3 from Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

134. Supplementary figure 5 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

135. Supplementary Figure 3 from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

136. Supplementary Figure 7 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

138. Supplementary Data from Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia

139. Supplementary Table 1 from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

140. Supplementary Figure Legends from Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

141. Supplementary Patient Data from Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

142. Data from Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming

143. Supplementary Methods and Legends from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

145. Supplementary Tables 1 - 3 from High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma

146. Supplementary Figures 1 - 5 from High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma

147. Supplementary Figures 1-2 from Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming

148. Data from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

149. Supplementary Figures 1-4, Tables 1-4 from Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene

Catalog

Books, media, physical & digital resources